TOKYO (ANN/YOMIURI SHIMBUN) – A startup born out of Osaka University is gearing up to seek approval for the commercial sale of heart muscle cell sheets derived from induced pluripotent stem (iPS) cells, as per the company’s announcement.
Cuorips Inc, based in Tokyo, plans to submit an application to the Health, Labour, and Welfare Ministry as early as June for authorisation to manufacture and distribute these sheets. They are intended for transplantation into the hearts of patients with myocardial infarctions (heart attacks) and related conditions. This endeavour marks a potential milestone as the first-ever utilisation of a regenerative medical treatment product derived from iPS cells. It’s anticipated that hospitals will soon adopt such medical products crafted from iPS cells.
The sheets are expected to be used to treat sufferers of ischemic heart diseases, in which the heart muscle is weakened by a heart attack or other cause. If symptoms become serious, the patients will need to receive heart transplants. But the number of heart donors is small, and heart transplantation also severely taxes the receiving patient’s body.
Yoshiki Sawa, a Distinguished Professor at Osaka University who also serves as the supreme technological manager of Cuorips, and his team produced heart muscle cells from human iPS cells, then processed them into the shape of sheets.
From January 2020 to March 2023, they conducted clinical tests on a total of eight patients with ischemic heart diseases. They grafted sheets of approximately 100 million cells onto each patient’s heart. Sawa and his team said that the treatment was confirmed to be safe for eight patients and all of them were able to return to normal life.
If the company can estimate the product’s effectiveness and other qualities despite the small size of the clinical trial, they plan to make use of a system in which they would be approved to produce the product under certain conditions for a limited amount of time. The company aims to obtain this approval in 2025.
Competition to develop medical products using iPS cells is growing increasingly fierce worldwide. In Japan, Osaka-based Sumitomo Pharma Co aims to apply for approval of nerve cells derived from iPS cells, to be administered to Parkinson’s disease sufferers, as early as fiscal 2024. This and other research toward practical uses of iPS cells continue apace.
